|
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) DCF -Bewertung
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) Bundle
Möchten Sie den inneren Wert von Zhejiang Hisoar Pharmaceutical Co., Ltd., beurteilen? Unser DCF-Taschenrechner (002099SZ) integriert reale Daten mit umfassenden Anpassungsoptionen, sodass Sie Ihre Prognosen verfeinern und Ihre Investitionsauswahl verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,941.4 | 2,471.4 | 2,484.8 | 2,704.1 | 2,171.9 | 2,029.1 | 1,895.7 | 1,771.1 | 1,654.7 | 1,546.0 |
| Revenue Growth, % | 0 | -15.98 | 0.5439 | 8.83 | -19.68 | -6.57 | -6.57 | -6.57 | -6.57 | -6.57 |
| EBITDA | 1,073.9 | 682.6 | 447.8 | 508.6 | -44.0 | 401.5 | 375.1 | 350.4 | 327.4 | 305.9 |
| EBITDA, % | 36.51 | 27.62 | 18.02 | 18.81 | -2.03 | 19.79 | 19.79 | 19.79 | 19.79 | 19.79 |
| Depreciation | 202.2 | 256.8 | 293.4 | 335.8 | 364.6 | 236.5 | 221.0 | 206.4 | 192.9 | 180.2 |
| Depreciation, % | 6.87 | 10.39 | 11.81 | 12.42 | 16.79 | 11.66 | 11.66 | 11.66 | 11.66 | 11.66 |
| EBIT | 871.7 | 425.8 | 154.5 | 172.7 | -408.6 | 165.0 | 154.1 | 144.0 | 134.5 | 125.7 |
| EBIT, % | 29.63 | 17.23 | 6.22 | 6.39 | -18.81 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 |
| Total Cash | 1,556.6 | 1,969.7 | 1,837.4 | 1,490.8 | 1,420.6 | 1,327.5 | 1,240.2 | 1,158.7 | 1,082.5 | 1,011.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 620.3 | .0 | 521.1 | 541.4 | 477.6 | 341.2 | 318.7 | 297.8 | 278.2 | 259.9 |
| Account Receivables, % | 21.09 | 0 | 20.97 | 20.02 | 21.99 | 16.81 | 16.81 | 16.81 | 16.81 | 16.81 |
| Inventories | 843.0 | 727.4 | 908.0 | 1,102.4 | 702.3 | 680.7 | 636.0 | 594.2 | 555.1 | 518.6 |
| Inventories, % | 28.66 | 29.43 | 36.54 | 40.77 | 32.33 | 33.55 | 33.55 | 33.55 | 33.55 | 33.55 |
| Accounts Payable | 601.7 | 613.2 | 1,028.8 | 995.0 | 603.3 | 613.8 | 573.5 | 535.8 | 500.6 | 467.6 |
| Accounts Payable, % | 20.46 | 24.81 | 41.4 | 36.8 | 27.78 | 30.25 | 30.25 | 30.25 | 30.25 | 30.25 |
| Capital Expenditure | -160.6 | -74.2 | -229.6 | -179.4 | -153.1 | -127.4 | -119.0 | -111.2 | -103.9 | -97.0 |
| Capital Expenditure, % | -5.46 | -3 | -9.24 | -6.64 | -7.05 | -6.28 | -6.28 | -6.28 | -6.28 | -6.28 |
| Tax Rate, % | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 |
| EBITAT | 736.3 | 345.9 | 119.6 | 150.8 | -368.1 | 138.8 | 129.6 | 121.1 | 113.2 | 105.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -83.7 | 1,275.9 | -102.7 | 58.7 | -84.4 | 416.3 | 258.4 | 241.4 | 225.6 | 210.7 |
| WACC, % | 6.61 | 6.59 | 6.57 | 6.62 | 6.63 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,145.0 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 219 | |||||||||
| Terminal Value | 8,416 | |||||||||
| Present Terminal Value | 6,112 | |||||||||
| Enterprise Value | 7,257 | |||||||||
| Net Debt | -367 | |||||||||
| Equity Value | 7,624 | |||||||||
| Diluted Shares Outstanding, MM | 1,616 | |||||||||
| Equity Value Per Share | 4.72 |
What You Will Receive
- Authentic 002099SZ Financial Data: Pre-populated with Zhejiang Hisoar Pharmaceutical's historical and projected figures for accurate analysis.
- Completely Customizable Template: Easily adjust critical variables such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Watch as the intrinsic value of Zhejiang Hisoar updates in real-time based on your modifications.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for reliable DCF outcomes.
- Intuitive Design: Straightforward layout and clear guidance suitable for users of all experience levels.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099SZ).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs to suit your analysis needs.
- Modifiable Forecast Assumptions: Customize growth rates, capital expenditures, and discount rates to reflect market conditions.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099SZ).
- Visual Dashboard and Charts: Graphical representations provide a summary of essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Zhejiang Hisoar Pharmaceutical Co., Ltd.'s pre-filled financial data and forecasts.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe how the DCF model updates in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Opt for Hisoar's Financial Calculator?
- Time Efficient: Skip building a DCF model from scratch – our tool is ready to go.
- Enhanced Precision: Dependable financial data and formulas minimize valuation errors.
- Completely Adaptable: Customize the model to align with your assumptions and forecasts.
- Simple to Analyze: Intuitive charts and outputs facilitate easy interpretation of results.
- Endorsed by Professionals: Crafted for experts who prioritize accuracy and functionality.
Who Can Benefit From This Product?
- Investors: Assess the valuation of Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099SZ) when considering stock transactions.
- CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts.
- Startup Founders: Gain insights into how established pharmaceutical companies like Zhejiang Hisoar are valued.
- Consultants: Provide clients with comprehensive valuation reports focused on Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099SZ).
- Students and Educators: Utilize real-world examples to enhance learning and application of valuation strategies.
What the Template Includes
- Pre-Filled DCF Model: Zhejiang Hisoar Pharmaceutical Co., Ltd.'s financial data preloaded for immediate use.
- WACC Calculator: Comprehensive calculations for Weighted Average Cost of Capital.
- Financial Ratios: Assess Zhejiang Hisoar's profitability, leverage, and efficiency.
- Editable Inputs: Modify assumptions such as growth, margins, and CAPEX to match your scenarios.
- Financial Statements: Annual and quarterly reports to facilitate in-depth analysis.
- Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.